ABSTRACT. Children with leukemia receive C N S therapy to improve long-term survival. Neurotoxic effects, such a s cognitive impairment, have been associated with this therapy. A rat model was developed to determine which agent, or combination of agents, in C N S therapy causes neurotoxicity. The agents examined were cranial irradiation (1000 cGy), methotrexate (2 or 4 mg/kg, intraperitoneally), and prednisolone (18 or 36 mglkg, intraperitoneally). Young Sprague-Dawley rats were exposed to each agent alone or to two-or three-agent combinations. Each therapy had matched controls that received sham radiation and/or intraperitoneal saline. Subsequent to exposure, spontaneous behavior was tested using a computer pattern recognition system, which recorded and classified behavior in a novel environment. Behavioral initiations, total times, and time structures were compared in therapy and control groups. Combined rather than single-agent therapies had more behavioral effects, and these were dose-and sex-dependent. Synergistic interactions between agents caused behavioral deficits, and components of the combination determined the abnormality. Some combinations interacted antagonistically, and thus mitigated behavioral deficits. Prednisolone was clearly pivotal to behavioral outcome. A low prednisolone dose-antagonized methotrexate preventing deficits. whereas a hieher ~rednisolone dose altered behavior by enhancing effects o f methotrexate and radiation. These findings emphasize that steroids are important in agent interactions. Their role in morbidity associated with leukemia treatment protocols may be equally important as that of methotrexate and cranial irradiation. Abbreviations ALL, acute lymphoblastic leukemia P, prednisolone treatment M, methotrexate treatment X, 1000 cGy cranial irradiation i.p., intraperitoneal BI, behavioral initiations BTT, behavioral total time BTS, behavioral time structure Treatment of the CNS is a standard component of therapy for childhood ALL. Although the efficacy of CNS treatment is well documented ( I). concerns remain about late-occuning neurotoxicity. The adverse effects, especially cognitive impairment. have been described extensively in clinical studies of children (2-5). The actual cause of these adverse effects. however. remains problematic. Treatment protocols for ALL typically involve multiple courses of systemic chemotherapy as well as CNS therapy. The latter usually involves intrathecal methotrexate. often alone or with intrathecal cytosine arabinoside and hydrocortisone. and sometimes with cranial irradiation and systemic steroids (6. 7). Some investigators have attributed neuropsychologic deficits primarily to cranial irradiation (8): others report that intrathecal methotrexate is equally neurotoxic (9). Still other investigators have suggested that it is the interaction of cranial irradiation and chemotherapy that is causal. and that the severity of neurotoxicity is directly proportional to the number of therapeutic modalities used (10. 1 1 ). Steroids are commonly given in combination with cranial irradiation and chemotherapy in treatment of leukemia. but they have not been considered as potentially toxic agents, despite their demonstrated effects in animals on neural development (6. 9. 12. 13).
Evaluation of neurotoxicity in the clinical context is usually undertaken on a retrospective basis because design of investigational protocols must be motivated primarily by consideration of efficacy. An animal model. however. allows for controlled prospective investigations. In previous studies. we demonstrated that a rat model provided a feasible approach to delineating the agents responsible for the neurotoxicity associated with CNS therapy (14. 15). Growth and behavioral effects of 1000 cGy cranial irradiation ( X ) were compared with those of X combined with 18 mg/kg prednisolone and 2 mg/kg methotrexate (PMX). Both X and PMX significantly affected growth ( 1 5). but X alone only minimally affected behavior. In contrast. PMX markedly disrupted behavior in male animals ( 14). The minimal behavioral effect of X contradicts clinical studies implicating cranial irradiation as the primary agent of neurotoxicity. Also, the sex specificity of the PMX response indicates that the relationship of neurotoxicity with the number of therapeutic modalities is not a simple one of direct proportionality.
The present study used the same animal model to further explore the cause of behavioral deficits induced by CNS therapies ( 14. 15). We evaluated the effects of three therapeutic agents: steroid, methotrexate. and cranial irradiation. These agents were antagonistic with respect to neurotoxicity.
MATERIALS A N D METHODS
simu~tancous~y the spontaneous behavior of one experimental Eight hundred ten pathogen-free Sprague-Dawley rats. 9 d old (day of birth = 0). were obtained from the Charles River Laboratories(Kingston. RI). They were shipped with dams and housed 10 pupsldam. Specified nonlittermates. each sex was assigned randomly to either an experimental group or its matched control. Certified Purina Rat Chow (5002, Ralston-Purina, St. Louis, MO) and tap water ad lihiflrrn were given to the rats except during the short behavioral observation periods. Light cycles were maintained as 12-h light (0600 h to 1800 h)/dark periods. All pups were weaned on d 2 1 and housed two per cage per sex. Individual body weight was recorded. but effects on growth are discussed in detail elsewhere ( 16). All procedures involving animals were conducted under the auspices of Forsyth's Institutional Animal Care and Use Committee.
The therapy groups are shown in The therapy groups receiving cranial irradiation were exposed on d 18 between 0900 and 1200 h using previously described procedures ( I 5). Rats were immobilized with pentobarbital anesthesia (25 mg/kg, i.p.). They were exposed six to eight at a time to a lateral beam of x-rays produced by an x-ray machine operating at 250 kV peaks with 0.35-mm copper filtration. Each animal was shielded with 2 mm of lead placed over the body and face. The eyes. oropharyngeal mucosa. and salivary tissues were protected while the skull was exposed from behind the eyes to the midposterior neck. The calculated mid-brain dose rate was 125 cGy/min: each irradiated brain received a total of 1000 cGy + 5% in a single fraction over 8 min. This dose approximated a biologic equivalent to the clinical dose of 3400 cGy given in 12-14 fractions ( 15). After pentobarbital anesthesia. control animals were sham irradiated by similar placement in the radiation beam but with complete shielding by 6 m m of lead.
Spontaneous behavior was analyzed in the rats at 6 wk and 4 m o of age using the same methodology as in our previous study (14) . All tests were conducted between 0900 and 1300 h. Two video cameras taking one frame per second were used to monitor rat and its matched control during a 15-min exploration of a novel environment. The video signals were transferred to a MICRO VAX I and a VAX 11/750 (Digital Equipment Corp.. Maynard. MA) for pattern analysis and behavioral classification of the data. The behaviors identified by the computer consisted of five major body positions (stand. sit. rear. walk, and lying down) and eight modifiers (groom. head turn, look, smell. sniff. turn. wash face. and blank or no recognized activity). The overall system of cameras. computers. computer software. and novel environment has been described in detail ( I 7).
Three measures of spontaneous behavior were made as in our previous study ( 14): a calculation of BI and BTT and a measure of BTS concerning the time distribution of the initiation of discrete acts and of sequences of joint acts.
('uli.lrluliotl (!/' BI. The frames in which a specific behavior began were totaled for each act during the 15-min observation period for each rat. The mean number of initiations per act was determined for each control and experimental group of rats. A I test was applied. and a 11 < 0.05 was required for statistical significance.
('c11r.rrluliotl ( f B 7 ' 7 : The number of frames that a behavior continued. including the frame it was initiated. was totaled for the 15-min observation period. The mean total time for each act in control and experimental groups of rats was determined. and statistical significance was evaluated using the t test. with a p < 0.05 required for a change to be considered significant.
C'ulr~~tlu~iot~ (!/'BT,I'. The time distribution and time sequence of behavioral acts were calculated using equations for K(t) which have been described extensively (18-71). For both sexes. the function K(t) was computed for 19 or 20 pairs per therapy group listed in Table I . a pair consisting of one experimental animal and one matched control. The K function was calculated for specific behavioral acts (cl.,y. sit. rear) or sequences of specific behavioral acts (sit. . . rear) (19) and for combined acts (c.,?.
attention or attention/groom) or sequences of combined acts ( c . ,~. attention . . . explore or attention/explore. . . groom/attention) (18). For each of these. a A K(t) [the difference between K(t) for the experimental animals and the matched controls] was calculated for eight time points (9. 5. 10. 90. 30. 45 . 100. and 900 s). At any one time point. when larger K values were found for one behavior over another. it meant that that particular behavior (or sequence) was more "clustered" in time and the other behavior was correspondingly more "dispersed" in time (it had increased time spacing between initiations). Whenever a behavioral act was initiated less than 10 times on average per animal, control or experimental, K(t) values were not determined for that behavior and related sequences. The bootstrap technique was used for estimating SD at each time point of the K function for a behavior, and the ad hoc criteria for significance of a difference between control and exposed groups were the same as in the study of PMX and X therapies (14) . The ad hoc RS statistic was developed to distinguish low level behavioral effects from noise (22). The RS encompasses all data produced in an experiment in one simple statistic. This is an advantage considering that the computer system generates over 100 behavioral measures of three distinctly different types (initiations, total times, and time structures) per experiment. The RS statistic indicates whether behavior is changed overall and the confidence level associated with that change. An RS statistic was determined for each therapy group in Table 1 and for the PMX and X therapies described in our previous study (14).
Statistical significance was set at the p < 0.01 level. Figure 1 illustrates the behavioral effects of each therapy in 6-wk-old animals and highlights the influence of dose. sex. and agent interactions on overall behavioral change. This screening information revealed the following characteristics of CNS therapies.
RESULTS
The cause 01 effects on behavior: combinations. Behavior was affected by more combined-agent therapies than single-agent therapies (Fig. 1) . The three-agent combination PlxMzX in males induced the most dramatic effect upon behavior, and the twoagent combinations usually altered behavior to a greater extent than the single agents. The only single agent that affected behavior was P18, and this effect occurred only in males. The data are not presented here, but we found that the steroid dexamethasone (1 mg/kg, i.p. on day 18) also affected behavior in males only (RS statistic at 6 wk of age = 0.279, p < 0.001). Single therapies Mz and X tended to affect behavior in females. although the effects were not statistically significant at any age.
Sex-influenced eflects on behavior. Behavioral response to each therapy was usually sex dependent (Fig. 1) . Females often exhibited behavioral effects at lower doses of combined therapies than males. For example, the M2X combination. which did not affect behavior of males, significantly altered behavior in females. P36M4 also affected only females. In contrast, males were affected more by the three-agent combinations, both PI8M2X and P36M4X (P36M4X data not shown). Figure 2 illustrates the sex dependency in response to PlxMIX; the three agents interacted producing essentially no behavioral effect in females but a dramatic behavioral effect in males. Virtually every male behavior altered by PI8M2X in our earlier study (14) was similarly affected (although not necessarily to the same extent) by PI8 alone. In short, the P l g effect in males was the best predictor of effects induced by the combination of PI8M2X in that sex. In males, therefore. the P I , effect was dominant.
Both males and females were affected by certain combination therapies. Both sexes were affected by M4X and PIxX. Although Figure 1 shows that behavior was altered significantly in 6-wkold P18X females but not males, changes emerged for PlsX males as well by 4 mo of age (RS statistic = 0.15 1, p < 0.00 1). With both sexes showing significant changes in response to P~R X and M4X, these combinations appeared to be among the more potent for affecting behavior.
Behavioral effects speciJic to combinutions. The behavioral deficits induced by combination therapies depended upon the combination's components. A combination including prednisolone and methotrexate in females primarily affected BI and BTT (12 significant B1 and BTT changes compared with four significant BTS changes), whereas radiation coupled with either meth-MULLENI otrexate or prednisolone affected BTS (significant BI and BTT changes never exceeded two). The statistically significant alterations in BI and BTT byPjhM4 in 6-wk-old females are listed in Table 2 . Figure 3 illustrates that MX combinations affecting BTS characteristically dispersed behaviors at 6 wk of age, i. time structure was dispersed in nine of I I behaviors altered in M4X females. In contrast, PX combinations affecting BTS characteristically clustered most behaviors at 6 wk. i.e. PlxX clustered I I of 13 behaviors altered in time structure in 6-wk-old females.
Outcome of agent interactions: antagonism or synergism. Behavioral outcome was highly dependent upon interactions of agents in a combination therapy. Some agent combinations interacted antagonistically, which led to protection or mitigation of behavioral effects caused by each agent alone. Behavior was not affected by PIRM2 in either sex or by M2X in males (Fig. I) . Figure 4 illustrates the protective antagonism by PIRM2 PIR consistently altered BTS in a way opposite from Mz. As a consequence, the two agents in combination acted to compensate for one another, so that the PlRMZ combination did not significantly alter behavior in either sex. The protective antagonism between M2 and X in males is shown in Table 3 . The effects of X on BI and BTT were mitigated when Mz and X were combined (M2X). Such protective antagonism between M2 and X was not evident in females, who instead displayed enhanced neurotoxicity via synergism when exposed to M2X. 4 Average seconds f SEM. The agent combinations that interacted synergistically led to effects greater than expected from either agent alone. Table 4 demonstrates synergistic interaction by the P3hM4 combination using BI and BTT measures. The combination effect of P36M4 was greater than the effects of either P36 or M4 alone, and it clearly was not a result of an additive reaction. The BTS measure also revealed synergisms, such as the response to MIX in males and females shown in Figure 5 . The sum of the effects of M4 alone and X alone did not equal the effects of M4X; rather, the combination effect was greater than expected from either agent alone. In fact, M4X in 6-wk-old females. for example. affected I I different behaviors and sequences, nine of which were not affected by either M4 alone or X alone.
Dose-ufictcd otitcotnc. Dose appeared to determine the outcome of agent interactions. Low-dose interactions could result in antagonism, and high-dose interactions in synergism. Figure  6 demonstrates dose-de~endent conversion of antagonism to synergism for MX and PM combinations using the BTS measure.
Because only one PX combination was examined, its dose dependency could not be determined. Additional dose-response studies are under way to expand these initial observations.
DISCUSSION
Behavioral deficits resulted primarily from combined agent therapies, consistent with findings of other studies in humans ( 10. 1 I ) and animals (23). No sinde aaent was the sole source of neurotbxicity. The components oFthege combinations interacted synergistically, not additively, to affect behavior. The combined effect (M2X, M4X. PIRX. Pj6M4) was greater than the sum of the effects of each component given alone (X, Mz. M4. PIX, or P36). The components, however, dictated the behavioral "signatures" found in the 6-wk-old rats. For example. a prednisolone and methotrexate combination increased the initiations and lengthened the durations of certain sedentary behaviors (sit, groom. and wash face) as in hypoactivity (24). A methotrexate and radiation combination dispersed BTS as in amphetamine hyperactivity (25), whereas a prednisolone and radiation combination clustered time structure similar to the neurotoxin triethyltin (24). A combination of all three agents clustered some BTS while dispersing others ( 14).
Among the combinations, however, one single agent, prednisolone. was pivotal to behavioral outcome by interacting with cranial irradiation and methotrexate. Depending upon the dose. prednisolone either antagonized methotrexate (PlxM2), resulting in protection from effects on behavior. or enhanced methotrexate and radiation effects (P3hM4. PIXX) and thus altered behavior. Other studies of CNS injury have shown that the effects of glucocorticoid steroids on neuronal viability also change from protective to deleterious depending upon dose, duration of treatment. and the steroid's chemical structure (26. 27).
Prednisolone clearly potentiated the effects of methotrexate and radiation in the three-agent combination PIRMZX. In males, exaggerated behavioral effects by PlxMzX contrasted the smaller effects by PI8 and the lack of effect by M2X. This prednisolone potentiation of radiation and methotrexate, the latter a wellknown antimetabolite (28). may be similar to other steroidantimetabolite interactions reported in the literature. Glucocorticoid steroids are known to potentiate hippocampal damage from metabolic insults by various neurotoxins (29) and ischemic injury (30) in rats. In turn, hippocampal damage is frequently linked with memory and learning deficits (31). Children who survive leukemia, whose treatment typically includes prolonged prednisone therapy. exhibit memory deficits (9, 32. 33). as do children treated with prednisone for asthma (34, 35). Alone. methotrexate alters development of synapses in the hippocampus of the neonatal rat (36). and prolonged glucoco~icoid exposure reduces hippocampal neuron number. thus contributing to the aging process and its associated memory deficits in rats (37. 38). Because the hippocampus was still developing (39) at the age rats were exposed here, alterations in hippocampal development may be important to consider in future studies of the potentiating effects of prednisolone. Given the links between steroids, antimetabolites. hippocampal damage, and memory deficits in the literature and the prednisolone interactions observed here, steroids assume a greater significance in this context. Steroids are used during remission induction of ALL (40. 41) and sometimes during CNS prophylactic therapy to reduce the somnolence syndrome (7). Synergism between methotrexate and cranial irradiation has driven attempts to prevent neurotoxicity, usually by excluding the latter from CNS therapy (9-1 1. 42). Apparently, however. synergisms involving steroids deserve equal attention when morbidity associated with leukemia treatment protocols is evaluated. This is especially important in an era when clinicians are replacing radiation with intrathecal methotrexate combined with cytosine arabinoside and hydrocortisone (intrathecal triple therapy).
Behavioral outcome subsequent to combination therapies was often sex dependent. Only females were affected by M?X, but both sexes were affected by M4X. Therefore. with some combinations, the sex difference appeared to be a function of dose. The distinct prednisolone sensitivity of males, however. indicated that other factors can be involved, i.c. variations in susceptibility due to differences in the timing of brain development. There is a sexual dimorphism in rat hepatic steroid metabolism that correlates with sexual dimorphism in growth hormone secretion (43). Sexual dimorphism in growth hormone secretion in turn subserves gender differences in hypothalamic somatostatin and growth hormone-releasing hormone gene expression or mode of signaling to pituitary somatotropes (44. 45). All these sexual dimorphisms are developmentally regulated, and that in the hypothalamus (44) is developing at about the age when animals were exposed in this study. Consequently, the involvement of combination therapies with sex-specific brain development, especially in the hypothalamus, is worth investigation. considering that sex sometimes determined whether or not outcome included neurotoxicity.
Antagonism between components of a combination is especially intriguing because of implications regarding antidotes.
Behavioral effects of Pi8 or Mz alone did not occur with the P , B M~ combination. Regardless of sex. P18 usually affected BTS in an opposite direction from M2. resulting in a functional or physiologic antagonism in which two chemicals had opposing effects on the same physiologic function. When M2 preceded X in males, the two agents also interacted antagonistically, eliminating behavioral effects as well as reducing effects on growth (16). As yet we have not observed antagonism between methotrexate and radiation in females. but other dose combinations need to be studied before drawing conclusions about protection by preirradiation methotrexate. Geyer et ul. (46) reported that methotrexate before radiation partially protected against white matter radionecrosis and forelimb paralysis in rats. Others have suggested that preirradiation methotrexate may help prevent CNS radiotoxicity in children and that it may benefit girls more
